ALXO

ALX OncologyF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

No material screener or newswire events are stored for this ticker yet.

Sentiment decomposition

30-day score

Company-55%

Macro-30%

Pulse-15%

The 30-day sentiment score is a decayed blend of Company, Macro, and Pulse components.

Recent headlines

Headline

Time

Relevance

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-08

23%

External coverage

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

2026-04-13

23%

External coverage

ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ...

2026-02-27

23%

External coverage

ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary

2026-02-27

23%

External coverage

ALX Oncology Q4 Earnings Call Highlights

2026-02-27

23%

External coverage

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

2026-02-27

23%

External coverage

ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

2026-02-19

External coverage

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

2025-12-07

23%

External coverage

As of 2026-05-08 • Updated scheduledSource: News desk